Pfizer is asked to suspend sales of painkiller

BMJ 2005; 330 doi: (Published 14 April 2005) Cite this as: BMJ 2005;330:862
  1. Jeanne Lenzer
  1. New York

    In a move that took experts by surprise, regulatory agencies in the United States and Europe have asked the drug maker Pfizer to suspend sales of its cyclooxygenase-2 (COX 2) inhibitor valdecoxib (Bextra).

    The US Food and Drug Administration's move comes less than two months after an advisory panel recommended to the FDA that the drug remain on the market (BMJ 2005;330: 440, 26 Feb).

    Pfizer said it …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to to receive unlimited access to all content on for 14 days.
    Sign up for a free trial